Published in Front Cardiovasc Med on May 19, 2015
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis | NCT00925002
Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis (EpiCardiAL) | NCT01511263
Cardiomyocyte-Specific Human Bcl2-Associated Anthanogene 3 P209L Expression Induces Mitochondrial Fragmentation, Bcl2-Associated Anthanogene 3 Haploinsufficiency, and Activates p38 Signaling. Am J Pathol (2016) 0.79
BRG1 and BRM SWI/SNF ATPases redundantly maintain cardiomyocyte homeostasis by regulating cardiomyocyte mitophagy and mitochondrial dynamics in vivo. Cardiovasc Pathol (2016) 0.78
The role of heat shock proteins and co-chaperones in heart failure. Philos Trans R Soc Lond B Biol Sci (2018) 0.76
Melusin Promotes a Protective Signal Transduction Cascade in Stressed Hearts. Front Mol Biosci (2016) 0.75
Aβ Amyloid Pathology Affects the Hearts of Patients With Alzheimer's Disease: Mind the Heart. J Am Coll Cardiol (2016) 0.75
Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem (2006) 22.87
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell (1998) 13.56
From Levinthal to pathways to funnels. Nat Struct Biol (1997) 10.58
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 10.39
Protein aggregation and neurodegenerative disease. Nat Med (2004) 9.51
Theory of protein folding. Curr Opin Struct Biol (2004) 7.64
The systemic amyloidoses. N Engl J Med (1997) 7.32
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Activation and regulation of the inflammasomes. Nat Rev Immunol (2013) 5.71
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell (2012) 4.29
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 3.93
Myocytes die by multiple mechanisms in failing human hearts. Circ Res (2003) 3.61
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell (2014) 3.25
The COP9 signalosome. Annu Rev Cell Dev Biol (2003) 3.25
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation (2006) 3.23
Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol (2005) 3.18
Arabidopsis COP9 is a component of a novel signaling complex mediating light control of development. Cell (1994) 2.89
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest (2000) 2.78
Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation (2008) 2.77
Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell (2014) 2.71
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A (2004) 2.32
Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res (2004) 2.25
The folding and evolution of multidomain proteins. Nat Rev Mol Cell Biol (2007) 2.16
Protein folding and modification in the mammalian endoplasmic reticulum. Annu Rev Biochem (2011) 2.13
Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity (2013) 2.02
Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem (2001) 1.97
Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol (2009) 1.96
Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation (2008) 1.95
Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart (1997) 1.90
The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp Physiol (2012) 1.85
The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat Immunol (2014) 1.83
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol (2011) 1.65
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 1.62
Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci (2000) 1.61
Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol (2011) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Selective degradation of aggregate-prone CryAB mutants by HSPB1 is mediated by ubiquitin-proteasome pathways. J Mol Cell Cardiol (2010) 1.54
Theoretical perspectives on protein folding. Annu Rev Biophys (2010) 1.53
Protein misfolding and human disease. Annu Rev Genomics Hum Genet (2006) 1.53
Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation (2008) 1.49
Inflammasomes in the CNS. Nat Rev Neurosci (2014) 1.44
Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy. J Am Coll Cardiol (2015) 1.42
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl (2003) 1.39
Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol (1989) 1.38
Structural insights into the COP9 signalosome and its common architecture with the 26S proteasome lid and eIF3. Structure (2010) 1.34
COP9 signalosome regulates autophagosome maturation. Circulation (2011) 1.32
Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol (2012) 1.30
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Consequences of COP9 signalosome and 26S proteasome interaction. FEBS J (2005) 1.24
Crystal structure of the human COP9 signalosome. Nature (2014) 1.20
Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem (2007) 1.17
Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. Mol Neurobiol (2007) 1.16
Structural properties of EGCG-induced, nontoxic Alzheimer's disease Aβ oligomers. J Mol Biol (2012) 1.16
Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res (2012) 1.15
Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol (2011) 1.14
Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol (2009) 1.13
Hold me tight: Role of the heat shock protein family of chaperones in cardiac disease. Circulation (2010) 1.13
Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. Proc Natl Acad Sci U S A (2013) 1.12
RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res (2014) 1.10
Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation (2010) 1.08
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A (1995) 1.08
Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci (2010) 1.04
Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy. PLoS One (2009) 1.04
Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol (2011) 1.04
Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells. J Neuroinflammation (2012) 1.03
Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A (2013) 1.01
Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev Med Chem (2008) 1.01
Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis (2010) 1.00
Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett (2011) 1.00
Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J (2006) 1.00
Hereditary periodic fever and reactive amyloidosis. Clin Exp Med (2005) 0.99
4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J (2003) 0.97
Necrosis-dependent and independent signaling of the RIP kinases in inflammation. Cytokine Growth Factor Rev (2013) 0.95
Transthyretin deposition in familial amyloidotic polyneuropathy. Curr Med Chem (2012) 0.93
Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res (2014) 0.93
Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta (2008) 0.92
New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood (1995) 0.92
Binding and stabilization of transthyretin by curcumin. Arch Biochem Biophys (2009) 0.92
Neddylation and deneddylation in cardiac biology. Am J Cardiovasc Dis (2014) 0.90
An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs (2014) 0.90
The COP9 signalosome is required for autophagy, proteasome-mediated proteolysis, and cardiomyocyte survival in adult mice. Circ Heart Fail (2013) 0.90
Protein misfolding in disease and small molecule therapies. Curr Top Med Chem (2012) 0.89
Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid (2008) 0.89
Chaperones and cardiac misfolding protein diseases. Curr Protein Pept Sci (2014) 0.87
Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infect Immun (2014) 0.87
NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity. Cell Mol Life Sci (2012) 0.86
Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochim Biophys Acta (2012) 0.85
Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs (2014) 0.83
Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid (2012) 0.82
Functional diversity of protein fibrillar aggregates from physiology to RNA granules to neurodegenerative diseases. Biochim Biophys Acta (2013) 0.82
Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis. Case Rep Nephrol (2014) 0.81
The role of the cofilin-actin rod stress response in neurodegenerative diseases uncovers potential new drug targets. Bioarchitecture (2012) 0.80
Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol (2012) 0.80
The effect of tafamidis on the QTc interval in healthy subjects. Br J Clin Pharmacol (2015) 0.78
Association of nucleotide-binding oligomerization domain-like receptor 3 inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy. Clin Chem Lab Med (2013) 0.78